<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Heart J</journal-id><journal-id journal-id-type="iso-abbrev">Eur. Heart J</journal-id><journal-id journal-id-type="publisher-id">eurheartj</journal-id><journal-title-group><journal-title>European Heart Journal</journal-title></journal-title-group><issn pub-type="ppub">0195-668X</issn><issn pub-type="epub">1522-9645</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28934837</article-id><article-id pub-id-type="pmc">5837241</article-id><article-id pub-id-type="doi">10.1093/eurheartj/ehx355</article-id><article-id pub-id-type="publisher-id">ehx355</article-id><article-categories><subj-group subj-group-type="heading"><subject>Fast Track Clinical Research</subject><subj-group subj-group-type="category-toc-heading"><subject>Heart Failure/Cardiomyopathy</subject></subj-group></subj-group><subj-group subj-group-type="category-oup-series"><subject>Editor's Choice</subject></subj-group><subj-group subj-group-type="category-oup-series"><subject>Fast Track</subject></subj-group></article-categories><title-group><article-title>Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hilfiker-Kleiner</surname><given-names>Denise</given-names></name><xref ref-type="aff" rid="ehx355-aff1">1</xref><xref ref-type="corresp" rid="ehx355-cor1"/><author-comment content-type="other"><p>
<sup>&#x02020;</sup> The first two authors contributed equally as first authors.</p></author-comment><xref ref-type="author-notes" rid="ehx355-FM1"/><!--<email>hilfiker.denise@mh-hannover.de</email>--></contrib><contrib contrib-type="author"><name><surname>Haghikia</surname><given-names>Arash</given-names></name><xref ref-type="aff" rid="ehx355-aff1">1</xref><xref ref-type="aff" rid="ehx355-aff2">2</xref><author-comment content-type="other"><p>
<sup>&#x02020;</sup> The first two authors contributed equally as first authors.</p></author-comment><xref ref-type="author-notes" rid="ehx355-FM1"/></contrib><contrib contrib-type="author"><name><surname>Berliner</surname><given-names>Dominik</given-names></name><xref ref-type="aff" rid="ehx355-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vogel-Claussen</surname><given-names>Jens</given-names></name><xref ref-type="aff" rid="ehx355-aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Schwab</surname><given-names>Johannes</given-names></name><xref ref-type="aff" rid="ehx355-aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Franke</surname><given-names>Annegret</given-names></name><xref ref-type="aff" rid="ehx355-aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Schwarzkopf</surname><given-names>Marziel</given-names></name><xref ref-type="aff" rid="ehx355-aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ehlermann</surname><given-names>Philipp</given-names></name><xref ref-type="aff" rid="ehx355-aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Pfister</surname><given-names>Roman</given-names></name><xref ref-type="aff" rid="ehx355-aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Michels</surname><given-names>Guido</given-names></name><xref ref-type="aff" rid="ehx355-aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Westenfeld</surname><given-names>Ralf</given-names></name><xref ref-type="aff" rid="ehx355-aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Stangl</surname><given-names>Verena</given-names></name><xref ref-type="aff" rid="ehx355-aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Kindermann</surname><given-names>Ingrid</given-names></name><xref ref-type="aff" rid="ehx355-aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>K&#x000fc;hl</surname><given-names>Uwe</given-names></name><xref ref-type="aff" rid="ehx355-aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Angermann</surname><given-names>Christiane E.</given-names></name><xref ref-type="aff" rid="ehx355-aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Schlitt</surname><given-names>Axel</given-names></name><xref ref-type="aff" rid="ehx355-aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Fischer</surname><given-names>Dieter</given-names></name><xref ref-type="aff" rid="ehx355-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Podewski</surname><given-names>Edith</given-names></name><xref ref-type="aff" rid="ehx355-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>B&#x000f6;hm</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="ehx355-aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Sliwa</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="ehx355-aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Bauersachs</surname><given-names>Johann</given-names></name><xref ref-type="aff" rid="ehx355-aff1">1</xref><xref ref-type="corresp" rid="ehx355-cor1"/><!--<email>bauersachs.johann@mh-hannover.de</email>--></contrib></contrib-group><aff id="ehx355-aff1">
<label>1</label>Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1. D-30625 Hannover, Germany</aff><aff id="ehx355-aff2">
<label>2</label>Department of Cardiology, Charit&#x000e9;-Universit&#x000e4;tsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany</aff><aff id="ehx355-aff3">
<label>3</label>Institute for Diagnostic and Interventional Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany</aff><aff id="ehx355-aff4">
<label>4</label>Universit&#x000e4;tsklinik f&#x000fc;r Innere Medizin 8 &#x02013; Schwerpunkt Kardiologie und Institut f&#x000fc;r Radiologie und Neuroradiologie, Klinikum N&#x000fc;rnberg S&#x000fc;d, Paracelsus, Medizinische Privatuniversit&#x000e4;t N&#x000fc;rnberg, Breslauer Str. 201, 90471 N&#x000fc;rnberg, Germany</aff><aff id="ehx355-aff5">
<label>5</label>Faculty of Medicine, University Leipzig, Clinical Trial Centre (KKS), ZKS Leipzig, Haertelstr. 16-18, D-04103 Leipzig, Germany</aff><aff id="ehx355-aff6">
<label>6</label>Department of Cardiology, Angiology, and Pneumology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany</aff><aff id="ehx355-aff7">
<label>7</label>Department of Cardiology, Pulmonology, and Vascular Medicine, University of Cologne, Cologne, Kerpenerstr. 62, 50937 K&#x000f6;ln, Germany</aff><aff id="ehx355-aff8">
<label>8</label>Department of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf, Germany</aff><aff id="ehx355-aff9">
<label>9</label>Department for Cardiology and Angiology, Angiologie, Center for Cardiovascular Research (CCR), Charit&#x000e9;-Universit&#x000e4;tsmedizin Berlin, Charit&#x000e9;platz 1, 10117 Berlin, Germany</aff><aff id="ehx355-aff10">
<label>10</label>Department of Internal Medicine III, University Hospital of the Saarland, 66421 Homburg/Saar, Germany</aff><aff id="ehx355-aff11">
<label>11</label>Department of Internal Medicine I, University Hospital Wuerzburg, Am Schwarzenberg 15, Haus A1597078 W&#x000fc;rzburg, Germany</aff><aff id="ehx355-aff12">
<label>12</label>Department of Medicine III, Medizinische Fakult&#x000e4;t der Martin Luther-Universit&#x000e4;t Halle-Wittenberg, Magdeburger Stra&#x003b2;e 8, 06108 Halle, Germany</aff><aff id="ehx355-aff13">
<label>13</label>Faculty of Health Sciences, Hatter Institute of Cardiology Research in Africa, 2 Anzio Road, Chris Barnard Building, 4th Floor, OBSERVATORY 7925, South Africa</aff><author-notes><corresp id="ehx355-cor1"><label>*</label> Corresponding authors. Tel: +49 511532 2531, Fax: +49 511532 3263, Email: <email>hilfiker.denise@mh-hannover.de</email>; Tel: +49 511 532 3841, Fax: +49 511 5325412, Email: <email>bauersachs.johann@mh-hannover.de</email></corresp><fn id="ehx355-FM1"><p>
<sup>&#x02020;</sup> The first two authors contributed equally as first authors.</p></fn><fn id="ehx355-FM2"><p>See page 2680 for the editorial comment on this article (doi: <related-article id="d35e292" related-article-type="companion" ext-link-type="doi" xlink:href="10.1093/eurheartj/ehx428">10.1093/eurheartj/ehx428</related-article>)</p></fn></author-notes><pub-date pub-type="ppub"><day>14</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-07-27"><day>27</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>7</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>38</volume><issue>35</issue><issue-title>Focus Issue on Cardiomyopathies</issue-title><fpage>2671</fpage><lpage>2679</lpage><history><date date-type="received"><day>10</day><month>4</month><year>2017</year></date><date date-type="rev-recd"><day>16</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ehx355.pdf"/><abstract><title>Abstract</title><sec><title>Aims</title><p>An anti-angiogenic cleaved prolactin fragment is considered causal for peripartum cardiomyopathy (PPCM). Experimental and first clinical observations suggested beneficial effects of the prolactin release inhibitor bromocriptine in PPCM.</p></sec><sec><title>Methods and results</title><p>In this multicentre trial, 63 PPCM patients with left ventricular ejection fraction (LVEF) &#x02264;35% were randomly assigned to short-term (1W: bromocriptine, 2.5&#x02009;mg, 7 days) or long-term bromocriptine treatment (8W: 5&#x02009;mg for 2&#x02009;weeks followed by 2.5&#x02009;mg for 6&#x02009;weeks) in addition to standard heart failure therapy. Primary end point was LVEF change (delta) from baseline to 6&#x02009;months assessed by magnetic resonance imaging. Bromocriptine was well tolerated. Left ventricular ejection fraction increased from 28&#x02009;&#x000b1;&#x02009;10% to 49&#x02009;&#x000b1;&#x02009;12% with a delta-LVEF of&#x02009;+&#x02009;21&#x02009;&#x000b1;&#x02009;11% in the 1W-group, and from 27&#x02009;&#x000b1;&#x02009;10% to 51&#x02009;&#x000b1;&#x02009;10% with a delta-LVEF of&#x02009;+&#x02009;24&#x02009;&#x000b1;&#x02009;11% in the 8W-group (delta-LVEF: <italic>P</italic>&#x02009;=&#x02009;0.381). Full-recovery (LVEF&#x02009;&#x02265;&#x02009;50%) was present in 52% of the 1W- and in 68% of the 8W-group with no differences in secondary end points between both groups (hospitalizations for heart failure: 1W: 9.7% vs. 8W: 6.5%, <italic>P</italic>&#x02009;=&#x02009;0.651). The risk within the 8W-group to fail full-recovery after 6&#x02009;months tended to be lower. No patient in the study needed heart transplantation, LV assist device or died.</p></sec><sec><title>Conclusion</title><p>Bromocriptine treatment was associated with high rate of full LV-recovery and low morbidity and mortality in PPCM patients compared with other PPCM cohorts not treated with bromocriptine. No significant differences were observed between 1W and 8W treatment suggesting that 1-week addition of bromocriptine to standard heart failure treatment is already beneficial with a trend for better full-recovery in the 8W group.</p></sec><sec><title>Clinical trial registration</title><p>ClinicalTrials.gov, study number: NCT00998556.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Peripartum cardiomyopathy</kwd><kwd>Bromocriptine</kwd><kwd>Prolactin</kwd><kwd>heart failure</kwd></kwd-group><counts><page-count count="9"/></counts></article-meta></front><body><sec><title>Introduction</title><p>Peripartum cardiomyopathy (PPCM) is increasingly recognized as a major cause of pregnancy related heart failure with high morbidity and mortality.<xref rid="ehx355-B1" ref-type="bibr"><sup>1&#x02013;4</sup></xref> The reported incidence of PPCM is regionally different ranging between 1 per 100 in Nigeria, 1 in 299 in Haiti to 1 in 1149&#x02013;3189 live births in the USA.<xref rid="ehx355-B1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="ehx355-B5" ref-type="bibr"><sup>5&#x02013;7</sup></xref> To date no evidence-based disease specific therapy is available for PPCM. Recommended treatment for PPCM is similar to that of heart failure from other aetiologies based on registry data and expert opinion.<xref rid="ehx355-B2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="ehx355-B4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="ehx355-B8" ref-type="bibr"><sup>8&#x02013;10</sup></xref> Although the aetiology of PPCM is still under investigation, in recent years a number of contributory mechanisms have been recognized to initiate and propagate the disease.<xref rid="ehx355-B1" ref-type="bibr"><sup>1&#x02013;4</sup></xref> Hereby, high levels of the nursing hormone prolactin and the production of a cleaved 16kDa N-terminal fragment of prolactin have emerged as potential key factors in the pathophysiology of PPCM. Experimental studies suggest that 16kDa prolactin induces profound endothelial damage and subsequent cardiomyocyte dysfunction and full-length prolactin promotes inflammation in PPCM while inhibition of prolactin release by the dopamine-D2-receptor agonist bromocriptine prevents onset of PPCM.<xref rid="ehx355-B11" ref-type="bibr"><sup>11&#x02013;14</sup></xref> Bromocriptine has been used for many years to stop lactation in postpartum women. In addition, prolactin-independent cytoprotective effects of bromocriptine were also shown in various organs including the heart.<xref rid="ehx355-B14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="ehx355-B15" ref-type="bibr"><sup>15</sup></xref> The strong improvement of cardiac function in previous reports including a clinical pilot study and register-based data demonstrating that prolonged treatment of PPCM patients with bromocriptine is feasible and may improve left ventricular (LV) recovery and clinical outcome<xref rid="ehx355-B12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="ehx355-B16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="ehx355-B17" ref-type="bibr"><sup>17</sup></xref> lend support to the hypothesis that prolonged bromocriptine treatment beyond the cumulative dose to stop lactation might be needed to achieve maximum clinical benefits. We therefore designed this randomized multicentre trial to compare the effects of prolonged bromocriptine treatment vs. short-term treatment sufficient to stop lactation in addition to guideline-based heart failure therapy<xref rid="ehx355-B9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="ehx355-B10" ref-type="bibr"><sup>10</sup></xref> on LV function and clinical outcomes in patients with PPCM.<xref rid="ehx355-B18" ref-type="bibr"><sup>18</sup></xref></p></sec><sec><title>Methods</title><p>The study design has been reported previously.<xref rid="ehx355-B18" ref-type="bibr"><sup>18</sup></xref></p><p>Detailed information on the study protocol and methods are provided in the <xref ref-type="supplementary-material" rid="sup1">Supplementary material online</xref>.</p></sec><sec><title>Results</title><sec><title>Screening, inclusion criteria, and randomization of study patients</title><p>From June 2010 until September 2015, 140 patients at 12 centres were screened for eligibility. Of these patients, 63 were included in the study while 77 patients did not fulfil the criteria for randomization. Reasons for exclusion were LVEF&#x02009;&#x0003e;&#x02009;35%, other reasons for heart failure, time since delivery more than 6&#x02009;months, social reasons, not agreed to participate in the study, drug abuse, incompliance and other reasons. All patients included in the study were postpartum. Accordingly, 32 patients were randomly assigned to receive 2.5&#x02009;mg bromocriptine for 1&#x02009;week (1W group) and 31 to receive 5&#x02009;mg bromocriptine for 2&#x02009;weeks followed by 2.5&#x02009;mg for 6&#x02009;weeks (8W group). In the 1W group, three patients withdrew consent after randomization, one was lost to follow-up, one did not undergo valid randomization. An additional patient of the 1W group was not treated according to the protocol but received higher dose of bromocriptine (up to 10&#x02009;mg) and relevantly longer so that the clinical event committee (CEC) decided to exclude her from all between-groups comparisons of efficacy end points. Therefore, 31 patients per group comprised the efficacy analysis set of patients. In total, 26 patients from the 1W group and 31 from the 8W group completed the study with follow-up data of 6&#x02009;months after diagnosis (<italic>Figure <xref ref-type="fig" rid="ehx355-F1">1</xref></italic>). Of these patients, 23 patients from the 1W and 28 patients from the 8W group met the imaging quality standards evaluated by the CEC in order to be taken into consideration for the primary end point (trial profile is shown in <italic>Figure <xref ref-type="fig" rid="ehx355-F1">1</xref></italic>).
</p><fig id="ehx355-F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Randomization, treatment, and follow-up of the patients. Left ventricular ejection fraction (LVEF), &#x000a7;patient was excluded from all between-groups comparisons for efficacy; *23 with adequate imaging quality for primary end point. # 28 with adequate imaging quality for primary end point. &#x000a7;One patient was not treated according to protocol and excluded from efficacy analyses.</p></caption><graphic xlink:href="ehx355f1"/></fig></sec><sec><title>Baseline characteristics of study patients</title><p>The characteristics of all randomized patients at baseline (Visit 1) are shown in <italic>Table <xref ref-type="table" rid="ehx355-T1">1</xref></italic>. More details about the baseline characteristics are provided in the <xref ref-type="supplementary-material" rid="sup1">Supplementary material online</xref>, <italic>Appendix</italic><italic>Table</italic><italic>s</italic><italic>S1</italic>&#x02013;<italic>S8</italic>. The groups were balanced with respect to baseline characteristics (age, gravida, parity, race, body mass index, haemodynamics, cardiac function New York Heart Association class), cardiovascular and pregnancy-related risk factors. Data for right ventricular ejection fraction (RVEF) as assessed by CMR were available for 44 patients. Baseline RVEF did not differ significantly between 1W (48&#x02009;&#x000b1;&#x02009;12%, <italic>n</italic>&#x02009;=&#x02009;20) and 8W (42&#x02009;&#x000b1;&#x02009;13%, <italic>n</italic>&#x02009;=&#x02009;24; 1W vs. 8W: <italic>P</italic>&#x02009;=&#x02009;0.20). The prevalence of impaired RV function (RVEF&#x02009;&#x0003c;&#x02009;40%) did not differ significantly between both groups (20% in 1W vs. 42% in 8W, <italic>P</italic>&#x02009;=&#x02009;0.19) although patients in the 8W group tended to have more often impaired RV function at baseline. No patient was diagnosed with PPCM in a previous pregnancy or was diagnosed during pregnancy. Diagnosis was made 1.6&#x02009;&#x000b1;&#x02009;1.6&#x02009;months after delivery and average time between first symptoms and diagnosis was 0.8&#x02009;&#x000b1;&#x02009;1.2&#x02009;months with no difference between groups. All patients were randomized postpartum. Randomization was done no more than 7 days after first diagnosis of PPCM. One patient was of African race, all other were of Caucasian race. Notably, use of guideline-based heart failure therapy including ACE inhibition or angiotensin receptor blocker (ARB), beta-blockade and mineralocorticoid receptor antagonist (MRA)<xref rid="ehx355-B9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="ehx355-B10" ref-type="bibr"><sup>10</sup></xref> during the study was high and did not differ between both groups (<italic>Table <xref ref-type="table" rid="ehx355-T1">1</xref></italic>). No patient in the 1W group resumed lactation after bromocriptine treatment.
<table-wrap id="ehx355-T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of all randomized patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="" span="1"/><col valign="top" align="char" char="" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Characteristic</th><th rowspan="1" colspan="1">1W bromocriptine (<italic>N</italic>&#x02009;=&#x02009;32)</th><th rowspan="1" colspan="1">8W bromocriptine (<italic>N</italic>&#x02009;=&#x02009;31)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age&#x02014;year</td><td rowspan="1" colspan="1">33.8&#x02009;&#x000b1;&#x02009;5.8</td><td rowspan="1" colspan="1">34.0&#x02009;&#x000b1;&#x02009;4.5</td></tr><tr><td rowspan="1" colspan="1">Median gravida (range)</td><td rowspan="1" colspan="1">1.5 (1&#x02013;7)</td><td rowspan="1" colspan="1">2 (1&#x02013;5)</td></tr><tr><td rowspan="1" colspan="1">Median parity (range)</td><td rowspan="1" colspan="1">1.5 (1&#x02013;7)</td><td rowspan="1" colspan="1">2 (1&#x02013;6)</td></tr><tr><td colspan="3" rowspan="1">Race or ethnic group&#x02014;number (%)<xref ref-type="table-fn" rid="tblfn3"><sup>a</sup></xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Caucasian</td><td rowspan="1" colspan="1">32 (100)</td><td rowspan="1" colspan="1">30 (97)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Black</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1 (3)</td></tr><tr><td rowspan="1" colspan="1">Systolic blood pressure&#x02014;mmHg</td><td rowspan="1" colspan="1">117&#x02009;&#x000b1;&#x02009;18</td><td rowspan="1" colspan="1">111&#x02009;&#x000b1;&#x02009;17</td></tr><tr><td rowspan="1" colspan="1">Heart rate&#x02014;beats per minute</td><td rowspan="1" colspan="1">90&#x02009;&#x000b1;&#x02009;16</td><td rowspan="1" colspan="1">84&#x02009;&#x000b1;&#x02009;12</td></tr><tr><td rowspan="1" colspan="1">Body mass index<xref ref-type="table-fn" rid="tblfn4"><sup>b</sup></xref></td><td rowspan="1" colspan="1">28.3&#x02009;&#x000b1;&#x02009;6.8</td><td rowspan="1" colspan="1">29.0&#x02009;&#x000b1;&#x02009;7.9</td></tr><tr><td rowspan="1" colspan="1">Serum creatinine&#x02014;mg/dL</td><td rowspan="1" colspan="1">0.8&#x02009;&#x000b1;&#x02009;0.2</td><td rowspan="1" colspan="1">0.9&#x02009;&#x000b1;&#x02009;0.2</td></tr><tr><td colspan="3" rowspan="1">Clinical features of heart failure</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Left ventricular ejection fraction&#x02014;(%)</td><td rowspan="1" colspan="1">28&#x02009;&#x000b1;&#x02009;10</td><td rowspan="1" colspan="1">27&#x02009;&#x000b1;&#x02009;9</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Right ventricular ejection fraction&#x02014;(%)<xref ref-type="table-fn" rid="tblfn5"><sup>c</sup></xref></td><td rowspan="1" colspan="1">48&#x02009;&#x000b1;&#x02009;12</td><td rowspan="1" colspan="1">42&#x02009;&#x000b1;&#x02009;13</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Median NT-proBNP&#x02014;pg/mL</td><td rowspan="1" colspan="1">2164 (1290&#x02013;3066)</td><td rowspan="1" colspan="1">2437 (1423&#x02013;4158)</td></tr><tr><td colspan="3" rowspan="1">NYHA functional class&#x02014;number (%)<xref ref-type="table-fn" rid="tblfn6"><sup>d</sup></xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;I</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1 (3.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;II</td><td rowspan="1" colspan="1">4 (12.5)</td><td rowspan="1" colspan="1">4 (12.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;III</td><td rowspan="1" colspan="1">10 (31.3)</td><td rowspan="1" colspan="1">9 (29.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;IV</td><td rowspan="1" colspan="1">18 (56.3)</td><td rowspan="1" colspan="1">17 (54.8)</td></tr><tr><td colspan="3" rowspan="1">Medical history&#x02014;number (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Hypertension</td><td rowspan="1" colspan="1">7 (21.9)</td><td rowspan="1" colspan="1">11 (35.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Diabetes</td><td rowspan="1" colspan="1">2 (6.3)</td><td rowspan="1" colspan="1">1 (3.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Smoker or former smoker</td><td rowspan="1" colspan="1">16 (50)</td><td rowspan="1" colspan="1">15 (48)</td></tr><tr><td colspan="3" rowspan="1">Pregnancy related conditions&#x02014;number (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Preeclampsia</td><td rowspan="1" colspan="1">5 (15,6)</td><td rowspan="1" colspan="1">8 (25.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Gestational diabetes</td><td rowspan="1" colspan="1">3 (9.4)</td><td rowspan="1" colspan="1">2 (6.5)</td></tr><tr><td colspan="3" rowspan="1">Treatment at randomization&#x02014;number (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;ACE inhibitor</td><td rowspan="1" colspan="1">30 (93.8) </td><td rowspan="1" colspan="1">27 (87.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Angiotensin receptor blocker</td><td rowspan="1" colspan="1">3 (9.4)</td><td rowspan="1" colspan="1">3 (9.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mineralcorticoid antagonist</td><td rowspan="1" colspan="1">27 (84.6)</td><td rowspan="1" colspan="1">25 (80.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Beta-blocker</td><td rowspan="1" colspan="1">29 (90.6)</td><td rowspan="1" colspan="1">31 (100)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Diuretic</td><td rowspan="1" colspan="1">28 (88.5)</td><td rowspan="1" colspan="1">28 (90.3)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Plus&#x02013;minus values are means&#x02009;&#x000b1;&#x02009;SD. There were no significant differences between the two groups. Data were missing for the following characteristics: N-terminal pro-B-type natriuretic peptide for 1 patient in the 1W group and 1 in the 8W group, respectively, body-mass index, for 1 patient in the 1W group. Percentages may not total 100 because of rounding. To convert the values for creatinine to micromoles per litre, multiply by 88.4.</p></fn><fn id="tblfn2"><p>IQR, interquartile range; NYHA, New York Heart Association.</p></fn><fn id="tblfn3"><label>a</label><p>Race or ethnic group was reported by the investigators.</p></fn><fn id="tblfn4"><label>b</label><p>The body mass index is the weight in kilograms divided by the square of the height in meters.</p></fn><fn id="tblfn5"><label>c</label><p>The data for right ventricular ejection fraction were available for <italic>n</italic>&#x02009;=&#x02009;44 patients (1W: <italic>n</italic>&#x02009;=&#x02009;20; 8W: <italic>n</italic>&#x02009;=&#x02009;24).</p></fn><fn id="tblfn6"><label>d</label><p>The data for NYHA class reflect the status of patients at the time of randomization.</p></fn></table-wrap-foot></table-wrap></p></sec><sec><title>Change in left ventricular function as primary end point</title><p>The LVEF increased from a mean of 28&#x02009;&#x000b1;&#x02009;10% at baseline to 49&#x02009;&#x000b1;&#x02009;12% at 6&#x02009;months in the 1W group (<italic>n</italic>&#x02009;=&#x02009;23), and from 27&#x02009;&#x000b1;&#x02009;10% to 51&#x02009;&#x000b1;&#x02009;10% in the 8W group (<italic>n</italic>&#x02009;=&#x02009;28) with a between-groups difference at 6-months follow-up of 2.0 [95% confidence limit: &#x02212;4.2; 8.2]% in favour of the 8W groups. Individual courses are presented in <italic>Figure <xref ref-type="fig" rid="ehx355-F2">2</xref>A</italic>. Delta LVEF was slightly higher in the 8W group (+24&#x02009;&#x000b1;&#x02009;11%) compared with the 1W group (+21&#x02009;&#x000b1;&#x02009;11%) but this was not statistically significant (<italic>P</italic>&#x02009;=&#x02009;0.381) with 2.5 [95% confidence limit: &#x02212;3.2; 8.3]%. In order to analyse effects of the two treatment concepts in more critically ill patients, a subgroup analysis was performed including only patients in whom baseline LVEF was &#x0003c;30%. As shown in <italic>Figure <xref ref-type="fig" rid="ehx355-F2">2</xref>B</italic>, the LVEF increased from a mean of 21&#x02009;&#x000b1;&#x02009;6% at baseline to 45&#x02009;&#x000b1;&#x02009;14% at 6&#x02009;months in the 1W group (<italic>n</italic>&#x02009;=&#x02009;14), and from 21&#x02009;&#x000b1;&#x02009;6% to 50&#x02009;&#x000b1;&#x02009;11% in the 8W group (<italic>n</italic>&#x02009;=&#x02009;18) again showing a slightly higher delta LVEF in the 8W subgroup (+29&#x02009;&#x000b1;&#x02009;10%) as compared with delta LVEF of the 1W subgroup (+24&#x02009;&#x000b1;&#x02009;11%) which was not statistically significant (8W vs. 1W: <italic>P</italic>&#x02009;=&#x02009;0.222). Between-groups differences at 6-months follow-up of LVEF change of 4.3 [95% confidence limit: &#x02212;4.6; 13.2]% and for LVEF change of 4.7 [95% confidence limit: &#x02212;2.9; 12.4]% in favour of the 8W groups were observed.
</p><fig id="ehx355-F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Analyses of global left ventricular ejection fraction (LVEF) change from baseline to 6&#x02009;months follow-up determined by CMR. (<italic>A</italic>) Individual courses of LVEF change from baseline to 6-months follow-up in the 1W group (<italic>n</italic>&#x02009;=&#x02009;23) and 8W group (<italic>n</italic>&#x02009;=&#x02009;28) with a between-groups difference at 6-months follow-up of 2.0% in favour of the 8W groups (<italic>P</italic>&#x02009;=&#x02009;0.38). (<italic>B</italic>) Individual courses of LVEF change from baseline to 6-months follow-up for the subgroup of patients with LVEF &#x0003c;30% at study entry in the 1 W group (<italic>n</italic>&#x02009;=&#x02009;14) and the 8W group (<italic>n</italic>&#x02009;=&#x02009;18) with between-groups differences at 6-months follow-up of 4.3% and for LVEF change of 4.7% in favour of the 8W groups (<italic>P</italic>&#x02009;=&#x02009;0.22).</p></caption><graphic xlink:href="ehx355f2"/></fig></sec><sec><title>Recovery rate of left ventricular function in peripartum cardiomyopathy patients after 6-months follow-up</title><p>After 6&#x02009;months follow-up 52% of the 1W-patients (<italic>n</italic>&#x02009;=&#x02009;32) showed full functional LV recovery (LVEF &#x02265;50%), 21% partial recovery (LVEF between 35% and &#x0003c;50%) and 28% no recovery (LVEF &#x0003c;35%), prematurely terminated the trial or had missing LVEF data. In the 8W arm (<italic>n</italic>&#x02009;=&#x02009;31), the respective rates were 68% for full functional recovery, 25% for partial recovery, and 7% for no recovery. Full recovery rates showed a descriptive benefit for the 8W group (68% compared with 52% in 1W group).
</p><fig id="ehx355-F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Outcome of patients at 6-months follow-up. (<italic>A</italic>) Left ventricular ejection fraction (LVEF) at 6-months follow-up according to predefined categories in all patients of the present study (treated 1W, <italic>n</italic>&#x02009;=&#x02009;32 or 8W, <italic>n</italic>&#x02009;=&#x02009;31 with bromocriptine, baseline LVEF &#x0003c;35%). Red columns illustrate the percentage of patients with no recovery (event or final LVEF &#x0003c;35%, prematurely terminated the trial or had missing LVEF data), yellow columns illustrate the percentage of patients with partial recovery (final LVEF 35% to&#x02009;&#x0003c;&#x02009;50%) and green columns depict percentage of women with complete recovery (final LVEF &#x02265;50%). (<italic>B</italic>) Step-wise change in LVEF measured by echocardiography during follow-up period in the 1 W (<italic>n</italic>&#x02009;=&#x02009;21) and the 8W group (<italic>n</italic>&#x02009;=&#x02009;24). The number 1&#x02013;5 marks time course of the five patients who did not recover LVEF &#x0003e;35% after 6-months. However, after &#x02265;12&#x02009;months Number 1 displayed a LVEF&#x02009;=&#x02009;62%, 2 a LVEF&#x02009;=&#x02009;47%, 3 and 4 a LVEF&#x02009;=&#x02009;50%, and 5 a LVEF&#x02009;=&#x02009;15%.</p></caption><graphic xlink:href="ehx355f3"/></fig><p>Fisher exact test (two-sided) resulted in <italic>P</italic>&#x02009;=&#x02009;0.283 and revealed an OR=&#x02009;0.508 [confidence limit: 0.173, 1.490] showing that&#x02014;although not significant&#x02014;the risk within the 8W group to fail &#x02018;full recovery&#x02019; after 6&#x02009;months is reduced.</p></sec><sec><title>Change in left ventricular function over time as assessed by echocardiography</title><p>We also analysed LVEF determined by echocardiography, which was performed immediately after patients' inclusion (Visit 1) with sequential performance at 2&#x02009;weeks (Visit 2), 1&#x02009;month (Visit 3), 3&#x02009;months (Visit 4) and 6&#x02009;months (Visit 5) after randomization (<italic>Figure <xref ref-type="fig" rid="ehx355-F3">3</xref></italic>B). Echocardiographic recordings meeting the quality standards of the core lab were available from 45 patients displaying a mean baseline LVEF of 23&#x02009;&#x000b1;&#x02009;7%. There was no difference in baseline LVEF measured by echocardiography between the 1W (23&#x02009;&#x000b1;&#x02009;7%, <italic>n</italic>&#x02009;=&#x02009;21) and the 8W (23&#x02009;&#x000b1;&#x02009;8%, <italic>n</italic>&#x02009;=&#x02009;24) group. After the 6&#x02009;months follow-up, the absolute improvement (delta LVEF) in the 1W group was&#x02009;+25&#x02009;&#x000b1;&#x02009;12% and&#x02009;+27&#x02009;&#x000b1;&#x02009;11% in the 8W group, which was not statistically significant (<italic>P</italic>&#x02009;=&#x02009;0.581).
</p><fig id="ehx355-F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Disease specific therapy with bromocritine. Scheme depicting inducers of increased oxidative stress in the peripartum maternal heart that mediate the generation of antiangiogenic 16kDa prolactin from the nursing hormone prolactin which drives PPCM as well as the hypothetic mechanisms how the prolactin release blocker bromocriptine together with standard heart failure medication interferes with it.</p></caption><graphic xlink:href="ehx355f4"/></fig></sec><sec><title>Secondary end points of study outcome</title><p>Secondary end points were hospitalization for heart failure, cardiac transplantation, and death of patient during trial, or combinations of these conditions (<italic>Table <xref ref-type="table" rid="ehx355-T2">2</xref></italic>). Among the patients of the 1W group 3 of 31 (=9.7%) and among the patients of the 8W group 2 of 31 (=6.5%) were hospitalized for heart failure until the end of study (<italic>Table <xref ref-type="table" rid="ehx355-T2">2</xref></italic>). Only one patient was listed for transplantation during the trial but was removed from the waiting list at follow-up due to improvement of the clinical condition and cardiac function. None of the patients received a left ventricular assist device (LVAD) or a heart transplantation, and no patient died. Altogether, the secondary end points of clinical events did not significantly differ between treatment groups (<italic>P</italic>&#x02009;=&#x02009;0.651).
<table-wrap id="ehx355-T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Effect of treatment on secondary end points</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="" span="1"/><col valign="top" align="char" char="" span="1"/><col valign="top" align="char" char="" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">End point</th><th rowspan="1" colspan="1">1W bromocriptine (<italic>N</italic>&#x02009;=&#x02009;31)<xref ref-type="table-fn" rid="tblfn8"><sup>a</sup></xref></th><th rowspan="1" colspan="1">8W bromocriptine (<italic>N</italic>&#x02009;=&#x02009;31)</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Hospitalization for heart failure</td><td rowspan="1" colspan="1">3 (9.7)</td><td rowspan="1" colspan="1">2 (6.5)</td><td rowspan="1" colspan="1">0.651</td></tr><tr><td rowspan="1" colspan="1">Cardiac transplantation</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">n.a.</td></tr><tr><td rowspan="1" colspan="1">Death of patient during trial period</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">n.a.</td></tr><tr><td rowspan="1" colspan="1">Combination of hospitalization for heart failure, cardiac transplantation or death</td><td rowspan="1" colspan="1">3 (9.7)</td><td rowspan="1" colspan="1">2 (6.5)</td><td rowspan="1" colspan="1">0.651</td></tr></tbody></table><table-wrap-foot><fn id="tblfn7"><p>Data are numbers of events (%).</p></fn><fn id="tblfn8"><label>a</label><p>One patient of the 1W group who was not treated according to the protocol but received higher dose of bromocriptine (up to 10&#x02009;mg) for a relevantly longer time was excluded from the endpoint analysis.</p></fn></table-wrap-foot></table-wrap></p></sec><sec><title>Safety of study treatment</title><p>A total of six serious adverse events (SAEs) in four patients were reported, and all SAEs occurred in patients of the 1W group (<italic>Table <xref ref-type="table" rid="ehx355-T3">3</xref></italic>). Therefore, no dose relationship can be concluded from the results. For three of the SAEs, causality was considered possible with respect to treatment with bromocriptine. In all three cases, SAE occurred after termination of bromocriptine therapy. These SAEs included two venous embolisms and one peripheral artery occlusion. A complete list of all adverse events (AEs) and adverse reactions is provided in the <xref ref-type="supplementary-material" rid="sup1">Supplementary material online</xref>, <italic>Appendix</italic><italic>Table</italic><italic>s</italic><italic>S12</italic>&#x02013;<italic>S14</italic>.
<table-wrap id="ehx355-T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Incidence of serious adverse events during the study by system organ class</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="char" char="" span="1"/><col valign="top" align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">System organ class</th><th rowspan="1" colspan="1">1W bromocriptine (<italic>N</italic>&#x02009;=&#x02009;32)<xref ref-type="table-fn" rid="tblfn10"><sup>a</sup></xref></th><th rowspan="1" colspan="1">Relation to bromocriptine</th><th rowspan="1" colspan="1">8W bromocriptine (<italic>N</italic>&#x02009;=&#x02009;31)</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">Cardiac disorders</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Coronary artery occlusion<xref ref-type="table-fn" rid="tblfn11"><sup>b</sup></xref></td><td rowspan="1" colspan="1">1 (3.2)</td><td rowspan="1" colspan="1">Not related</td><td rowspan="1" colspan="1">0(0)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td colspan="5" rowspan="1">Musculoskeletal disorders</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Chest pain</td><td rowspan="1" colspan="1">1 (3.2)</td><td rowspan="1" colspan="1">Unlikely related</td><td rowspan="1" colspan="1">0(0)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td colspan="5" rowspan="1">Respiratory disorders</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Dyspnoea</td><td rowspan="1" colspan="1">1 (3.2)</td><td rowspan="1" colspan="1">Unlikely related</td><td rowspan="1" colspan="1">0(0)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td colspan="5" rowspan="1">Vascular disorders</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Venous Embolism</td><td rowspan="1" colspan="1">2 (6.4)</td><td rowspan="1" colspan="1">Possibly related</td><td rowspan="1" colspan="1">0(0)</td><td rowspan="1" colspan="1">0.491</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Peripheral artery occlusion</td><td rowspan="1" colspan="1">1 (3.2)</td><td rowspan="1" colspan="1">Possibly related</td><td rowspan="1" colspan="1">0(0)</td><td rowspan="1" colspan="1">1.000</td></tr></tbody></table><table-wrap-foot><fn id="tblfn9"><p>Data are numbers of events (%).</p></fn><fn id="tblfn10"><label>a</label><p>The one patient of the 1W group who was not treated according to the protocol but received higher dose of bromocriptine (up to 10&#x02009;mg) for a relevantly longer time was included in the safety analyses.</p></fn><fn id="tblfn11"><label>b</label><p>Occlusion was due to air embolism as a complication during coronary angiography.</p></fn></table-wrap-foot></table-wrap></p></sec><sec><title>Comparison of outcome with IPAC study</title><p>As a limitation of our study, we do not have a placebo control group because it was considered unethical given the results of previous registry data and pilot studies<xref rid="ehx355-B12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="ehx355-B16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="ehx355-B17" ref-type="bibr"><sup>17</sup></xref> and the risk for mastitis for stopping lactation without medical support. We therefore compared a subgroup of our collective characterized by a baseline LVEF &#x0003c;30% (echocardiography) with a subgroup of PPCM patients with a baseline LVEF &#x0003c;30% (echocardiography) from the Investigation in Pregnancy Associate Cardiomyopathy (IPAC) collective, which has been analysed over the same time period and obtaining comparable standard therapy for heart failure but no bromocriptine.<xref rid="ehx355-B19" ref-type="bibr"><sup>19</sup></xref> In the IPAC subgroup (<italic>n</italic>&#x02009;=&#x02009;27 patients), 37% remained in severe heart failure after a follow-up period of 6&#x02013;12&#x02009;months. In addition, the rate of transplantation and/or use of LVAD was 19%, and the mortality rate was 15% (<italic>Table <xref ref-type="table" rid="ehx355-T4">4</xref></italic>). In the present study, 37 patients (<italic>n</italic>&#x02009;=&#x02009;18 in the 1W and <italic>n</italic>&#x02009;=&#x02009;19 in the 8W group) displayed a baseline LVEF &#x0003c;30% with at least 6-months follow-up. No patient in the 1W or the 8W group died, needed heart transplantation or a LVAD (<italic>Table <xref ref-type="table" rid="ehx355-T4">4</xref></italic>). In the 1W group two and in the 8W group three patients did not recover LVEF above 35% after 6&#x02009;months. Follow-up analyses after &#x02265;12&#x02009;months were available for these five patients showing that three patients displayed complete recovery (LVEF &#x02265;50%), and one patient showed substantial recovery with an LVEF of 47% and only one patient in the 8W group remained in severe heart failure (<italic>Table <xref ref-type="table" rid="ehx355-T4">4</xref></italic>). However, this patient showed poor adherence to standard heart failure medication during follow-up.
<table-wrap id="ehx355-T4" orientation="portrait" position="float"><label>Table 4</label><caption><p><bold>Effect of treatment on outcome in</bold> peripartum cardiomyopathy <bold>patients with</bold> left ventricular ejection fraction <bold>&#x0003c;30% in the bromocriptine study (treated either with 1W or 8W bromocriptine) compared with the IPAC study without bromocriptine treatment</bold><xref rid="ehx355-B19" ref-type="bibr"><sup>19</sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="char" char="" span="1"/><col valign="top" align="char" char="" span="1"/><col valign="top" align="char" char="" span="1"/><col valign="top" align="char" char="" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Follow-up characteristics</th><th rowspan="1" colspan="1">1W bromocriptine baseline LVEF &#x0003c;30% (<italic>n</italic>&#x02009;=&#x02009;18)</th><th rowspan="1" colspan="1">8W bromocriptine baseline LVEF &#x0003c;30% (<italic>n</italic>&#x02009;=&#x02009;19)</th><th rowspan="1" colspan="1">1W and 8W bromocriptine baseline LVEF &#x0003c;30% (<italic>n</italic>&#x02009;=&#x02009;37)</th><th rowspan="1" colspan="1">IPAC study placebo baseline LVEF &#x0003c;30% (<italic>n</italic>&#x02009;=&#x02009;27)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">LVEF &#x0003c;35%</td><td rowspan="1" colspan="1">0% (0/18)</td><td rowspan="1" colspan="1">5% (1/19)</td><td rowspan="1" colspan="1">3% (1/37)</td><td rowspan="1" colspan="1">37%</td></tr><tr><td rowspan="1" colspan="1">LVEF 35&#x02013;49%</td><td rowspan="1" colspan="1">22% (6/18)</td><td rowspan="1" colspan="1">37% (7/19)</td><td rowspan="1" colspan="1">35% (13/37)</td><td rowspan="1" colspan="1">26%</td></tr><tr><td rowspan="1" colspan="1">Full recovery, LVEF &#x02265;50</td><td rowspan="1" colspan="1">67% (12/18)</td><td rowspan="1" colspan="1">58% (11/19)</td><td rowspan="1" colspan="1">62% (23/37)</td><td rowspan="1" colspan="1">37%</td></tr><tr><td rowspan="1" colspan="1">LVAD and HTX</td><td rowspan="1" colspan="1">0% (0/18)</td><td rowspan="1" colspan="1">0% (0/19)</td><td rowspan="1" colspan="1">0% (0/37)</td><td rowspan="1" colspan="1">19% (5/27)</td></tr><tr><td rowspan="1" colspan="1">Death</td><td rowspan="1" colspan="1">0% (0/18)</td><td rowspan="1" colspan="1">0% (0/19)</td><td rowspan="1" colspan="1">0% (0/37)</td><td rowspan="1" colspan="1">15% (4/27)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn12"><p>LVEF was analysed by echocardiography in the core labs of both studies. Follow-up in the IPAC study was 12&#x02009;months, follow-up in our study was at 6&#x02013;36&#x02009;months.</p></fn><fn id="tblfn13"><p>LVEF, left ventricular ejection fraction; LVAD, left ventricular assist device; HTX, heart transplantation.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec><title>Discussion</title><p>Our study is the first prospective, randomized, and multicentre trial at adequate size to test short- vs. long-term inhibition of prolactin by bromocriptine as a causal therapy for PPCM. It demonstrates that inhibition of prolactin release with long-term or short-term bromocriptine in addition to standard therapy for heart failure in patients with severe forms of PPCM is associated with a high recovery rate and very low rate of adverse outcome. In fact no patient died or needed a heart transplantation or a LVAD and full recovery rate was higher than in any ever published PPCM collective.<xref rid="ehx355-B3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="ehx355-B6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="ehx355-B16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="ehx355-B20" ref-type="bibr"><sup>20&#x02013;26</sup></xref> In addition, our study population tolerated bromocriptine well suggesting that both, short- and long-term application appear to be safe since attention was paid to ensure sufficient anticoagulant therapy during treatment. The study did not detect a significant benefit for prolonged inhibition of prolactin release with bromocriptine in addition to standard therapy for heart failure in increasing LVEF or reducing hospitalization for heart failure compared with short-term bromocriptine application sufficient to stop lactation in patients with PPCM. However, we observed a trend for more patients reaching full recovery after 6&#x02009;months in the 8W group suggesting a small benefit of prolonged bromocriptine treatment.</p><p>Despite advances in understanding the pathomechanisms of PPCM, clinical trials testing disease-specific therapeutics beyond standard therapy for heart failure in this condition are scarce.<xref rid="ehx355-B2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="ehx355-B4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="ehx355-B8" ref-type="bibr"><sup>8&#x02013;10</sup></xref> The nursing hormone prolactin and specifically its cleaved 16&#x02009;kDa form is considered to play a key role in the pathophysiology of PPCM (<italic>Figure <xref ref-type="fig" rid="ehx355-F4">4</xref></italic>).<xref rid="ehx355-B12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="ehx355-B13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="ehx355-B16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="ehx355-B17" ref-type="bibr"><sup>17</sup></xref> However, unlike the placebo controlled study by Sliwa <italic>et al.</italic><xref rid="ehx355-B17" ref-type="bibr"><sup>17</sup></xref> the present study was not designed to compare bromocriptine therapy with placebo but to compare two different dose regimes of bromocriptine in severely diseased PPCM patients: A short-term regime that is sufficient to suppress lactation and a long-term regime that may exert additional cardioprotective effects.</p><p>The primary end point of our study, the global improvement in LVEF at 6&#x02009;months, was not significantly different among the short-term and long-term bromocriptine groups, although the long-term treatment descriptively showed a higher rate of predefined full LV recovery. It is important to note, that the overall outcome among all patients enrolled in this study was better than the outcome of any prospective study on PPCM reported so far: Only 7% of all patients remaining in the study with complete data sets were still in severe LV dysfunction (EF &#x0003c;35%) at 6-months follow-up and only 3% remained in heart failure thereafter. Moreover, none of the patients experienced a major adverse event including death, cardiac transplantation or LVAD implantation. It has to be noted that all patients were randomized no longer than 7 days after first diagnosis in a severe disease state (LVEF &#x02264;35%), thereby no selection for more stable patients was ensured. In a comparable group of patients in Germany, we previously reported a 15% treatment failure in a German registry with prospective data of 96 PPCM patients despite standard heart failure drug therapy.<xref rid="ehx355-B1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="ehx355-B16" ref-type="bibr"><sup>16</sup></xref> Importantly, in the German registry the percentage of patients with persistent severe LV dysfunction was significantly higher among those patients who did not receive bromocriptine. The rate of maternal major adverse events among all patients in the German registry was 10% with a mortality rate of 2%. Interestingly, in the recent prospective North American IPAC study including PPCM patients with LVEF&#x02009;&#x0003c;&#x02009;45% a comparable event rate of 7% and a mortality rate of about 4% were reported.<xref rid="ehx355-B19" ref-type="bibr"><sup>19</sup></xref> In the IPAC study a subgroup of severely diseased patients with an LVEF &#x0003c;30% was analysed of whom 37% reached an LVEF &#x02265;50% (full recovery) and an equal number, 37% experienced a major event (transplantation/LVAD: 19% or death: 15%) or a final LVEF &#x0003c;35%.<xref rid="ehx355-B19" ref-type="bibr"><sup>19</sup></xref> We identified a similar subgroup in our study that presented with a baseline LVEF &#x0003c;30%, that however displayed a substantially better outcome (62% full recovery and 0% LVAD, HTX or death, only 3% with persistently LVEF &#x0003c;35%). Although this indirect comparison has to be interpreted with caution given some differences in the population characteristics, in particular the proportion of patients with African origin (2% in our study vs. 27% in the IPAC study) for whom prognosis might be worse,<xref rid="ehx355-B21" ref-type="bibr"><sup>21</sup></xref> it seems to further support the view that there is a benefit of bromocriptine treatment. In fact, also in non-African countries, i.e. for example in Turkey, mortality rates for PPCM between 25 and 30% were reported.<xref rid="ehx355-B20" ref-type="bibr"><sup>20</sup></xref> In view of these studies, a treatment concept that combines short-term low dose bromocriptine with standard heart failure therapy, as evaluated in the present study, appears to be associated with a better outcome, although a number of factors have to be taken into account which may have an impact on patient outcome, such as different ethnicities with potentially different genetic dispositions and different medical care opportunities.</p><p>An important reason for the beneficial effect of bromocriptine treatment may also be the associated ablactation which enables early optimal heart failure treatment with beta-blockade, ACE inhibition, MRA, and ivabradine.<xref rid="ehx355-B2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="ehx355-B8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="ehx355-B27" ref-type="bibr"><sup>27</sup></xref> No controlled studies have ever analysed the potential adverse effects of heart failure medication transferred to the infant in the breast milk, whereas normal growth percentiles and no adverse outcome were observed for the infants of PPCM patients in South Africa who terminated breastfeeding.<xref rid="ehx355-B17" ref-type="bibr"><sup>17</sup></xref> Thus, terminating breastfeeding with bromocriptine appears to be safe for the child and may enable implementation of early intensive heart failure therapy at high dosages associated with faster recovery of the mother enabling her to better care for her newborn.</p><p>Some concerns have been raised about a potential risk for cerebral and cardiovascular complications in patients treated with high doses of bromocriptine.<xref rid="ehx355-B28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="ehx355-B29" ref-type="bibr"><sup>29</sup></xref> However, our observation that no adverse event associated with bromocriptine occurred during bromocriptine treatment in both groups suggests that bromocriptine (together with anticoagulant therapy) is safe and potentially effective in PPCM patients although the optimal dosage and duration of therapy to achieve maximal cardioprotective effects still remains a matter of investigation. Future studies should also explore whether extended prophylactic anticoagulation beyond the period of bromocriptine treatment is required in these patients with a considerable risk of thromboembolism.</p><p>Recent nation-wide observations and population-based studies estimated a rise in incidence of PPCM worldwide,<xref rid="ehx355-B5" ref-type="bibr"><sup>5&#x02013;7</sup></xref> emphasizing that future research should focus on investigating preventive strategies. Moreover, modern echocardiography and cardiac magnetic resonance imaging have broadened the phenotypic profile of PPCM showing for example, that in about one-third of PPCM patients the right ventricle is affected by the disease with lower likelihood to recover despite optimal therapy.<xref rid="ehx355-B30" ref-type="bibr"><sup>30</sup></xref> The phenotypic heterogeneity of this disease with variable outcome may reflect additional contributing factors such as genetic or (auto-)immune mechanisms<xref rid="ehx355-B31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="ehx355-B32" ref-type="bibr"><sup>32</sup></xref> that may determine the course of disease and the clinical outcome. Thus, the challenge of future research will be to elaborate specific therapeutic concepts for patients who are likely to be refractory to current treatment options. Since improvement of LV function was similar between the two bromocriptine regiments, an outcome study testing the concept appears worthwhile. Currently, our own experience suggests that critically ill patients (baseline LVEF &#x0003c;25%, cardiogenic chock) may profit from a prolonged treatment with a higher initial dosage of bromocriptine (see <xref ref-type="supplementary-material" rid="sup1">Supplementary material online</xref>, <italic>Figure</italic><italic>S</italic><italic>1</italic>), a feature that is also supported by the trend for faster full-recovery in the 8W group. This hypothesis needs to be scrutinized in a prospective randomized outcome trial.</p><p>In conclusion, the findings of our study further support a potential benefit of bromocriptine in addition to standard heart failure therapy and best supportive care in PPCM patients (<italic>Figure <xref ref-type="fig" rid="ehx355-F4">4</xref></italic>). It appears that a short low dose bromocriptine therapy aiming to stop lactation is sufficient in most forms of PPCM. However, the limited numbers of patients available in single countries warrant large international prospective registries, i.e. PPCM EORP registry [ESC EURObservational Research Programme (<ext-link ext-link-type="uri" xlink:href="http://www.eorp.org">http://www.eorp.org</ext-link>)], to get further insights into the efficiency of treatment strategies.</p></sec><sec><title>Manufacturer of the study drug</title><p>AbZ-Pharma GmbH</p></sec><sec sec-type="supplementary-material"><title>Supplementary material</title><p>
<xref ref-type="supplementary-material" rid="sup1">Supplementary material</xref> is available at <italic>European Heart Journal</italic> online.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sup1"><label>Supplementary Appendix</label><media xlink:href="ppcm_supplemantary_appendix_final072017_ehx355.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sup2"><label>Supplementary Table</label><media xlink:href="ppcm-screened_included_patientsv1_ehx355.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>We thank S. Gutzke, B. Ritter, S. Tammen, M. Kasten, and M. Jungesblut for technical assistance.</p><sec><title>Funding</title><p>This trial was funded by the German Federal Ministry of Education and Research (BMBF), the cluster of excellence Rebirth II (German Research Foundation), and the Foundation Leducq and the &#x02018;Junge Akademie&#x02019; Programme of the Hannover Medical School to A.H. ClinicalTrials.gov number: NCT00998556.</p><p>
<bold>Conflict of interest:</bold> None of the members of the study team and study committees has a conflict of interest or financial interest, arrangement or affiliation with the manufacturer of the study drug. <italic>Steering Committee:</italic> D.H-K. (authorized representative of the sponsor), J.B. (coordinating investigator), A.H. (representative of the coordinating investigator), and M.B. (University of Saarland). <italic>Safety Monitoring Board Members:</italic> J. McMurray (University of Glasgow), A. Koch (Hannover Medical School), G. P. Meyer (Hannover) and N. Marx (University of Aachen). <italic>Clinical Event Committee:</italic> Stefan Anker (G&#x000f6;ttingen), Kenneth Dickstein (University of Bergen) and Dirk J. van Veldhuisen (University of Groningen), <italic>Study management</italic> Clinical Trial Centre at the University of Leipzig (ZKS Leipzig).</p></sec></ack><ref-list><title>References</title><ref id="ehx355-B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sliwa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fett</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Elkayam</surname><given-names>U.</given-names></name></person-group>
<article-title>Peripartum cardiomyopathy</article-title>. <source>Lancet</source><year>2006</year>;<volume>368</volume>:<fpage>687</fpage>&#x02013;<lpage>693</lpage>.<pub-id pub-id-type="pmid">16920474</pub-id></mixed-citation></ref><ref id="ehx355-B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Haghikia</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nonhoff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bauersachs</surname><given-names>J.</given-names></name></person-group>
<article-title>Peripartum cardiomyopathy: current management and future perspectives</article-title>. <source>Eur Heart J</source><year>2015</year>;<volume>36</volume>:<fpage>1090</fpage>&#x02013;<lpage>1097</lpage>.<pub-id pub-id-type="pmid">25636745</pub-id></mixed-citation></ref><ref id="ehx355-B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sliwa</surname><given-names>K.</given-names></name></person-group>
<article-title>Pathophysiology and epidemiology of peripartum cardiomyopathy</article-title>. <source>Nat Rev Cardiol</source><year>2014</year>;<volume>11</volume>:<fpage>364</fpage>&#x02013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">24686946</pub-id></mixed-citation></ref><ref id="ehx355-B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sliwa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Petrie</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Mebazaa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pieske</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Buchmann</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Regitz-Zagrosek</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Schaufelberger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tavazzi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>van Veldhuisen</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Watkins</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Seferovic</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Elkayam</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Pankuweit</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Papp</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Mouquet</surname><given-names>F</given-names></name>, <name name-style="western"><surname>McMurray</surname><given-names>JJ.</given-names></name></person-group>
<article-title>Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy</article-title>. <source>Eur J Heart Fail</source><year>2010</year>;<volume>12</volume>:<fpage>767</fpage>&#x02013;<lpage>778</lpage>.<pub-id pub-id-type="pmid">20675664</pub-id></mixed-citation></ref><ref id="ehx355-B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brar</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Sandhu</surname><given-names>GK</given-names></name>, <name name-style="western"><surname>Jorgensen</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Parikh</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>AY.</given-names></name></person-group>
<article-title>Incidence, mortality, and racial differences in peripartum cardiomyopathy</article-title>. <source>Am J Cardiol</source><year>2007</year>;<volume>100</volume>:<fpage>302</fpage>&#x02013;<lpage>304</lpage>.<pub-id pub-id-type="pmid">17631087</pub-id></mixed-citation></ref><ref id="ehx355-B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kolte</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Khera</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Aronow</surname><given-names>WS</given-names></name>, <name name-style="western"><surname>Palaniswamy</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mujib</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ahn</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Jain</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Gass</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Panza</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Fonarow</surname><given-names>GC.</given-names></name></person-group>
<article-title>Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study</article-title>. <source>J Am Heart Assoc</source><year>2014</year>;<volume>3</volume>:<fpage>e001056.</fpage><pub-id pub-id-type="pmid">24901108</pub-id></mixed-citation></ref><ref id="ehx355-B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sliwa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Boehm</surname><given-names>M.</given-names></name></person-group>
<article-title>Incidence and prevalence of pregnancy associated heart disease</article-title>. <source>Cardiovasc Res</source><year>2014</year>;<volume>101</volume>:<fpage>554</fpage>&#x02013;<lpage>560</lpage>.<pub-id pub-id-type="pmid">24459193</pub-id></mixed-citation></ref><ref id="ehx355-B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bauersachs</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Arrigo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Veltmann</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Coats</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Crespo-Leiro</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>De Boer</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>van der Meer</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Maack</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mouquet</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Petrie</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Piepoli</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Regitz-Zagrosek</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Schaufelberger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Seferovic</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tavazzi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ruschitzka</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Mebazaa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sliwa</surname><given-names>K.</given-names></name></person-group>
<article-title>Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy</article-title>. <source>Eur J Heart Fail</source><year>2016</year>;<volume>18</volume>:<fpage>1096</fpage>&#x02013;<lpage>1105</lpage>.<pub-id pub-id-type="pmid">27338866</pub-id></mixed-citation></ref><ref id="ehx355-B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ponikowski</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Voors</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Anker</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Bueno</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Cleland</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Coats</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Falk</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Gonzalez-Juanatey</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Harjola</surname><given-names>VP</given-names></name>, <name name-style="western"><surname>Jankowska</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Jessup</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Linde</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Nihoyannopoulos</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Parissis</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Pieske</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Riley</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Rosano</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Ruilope</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Ruschitzka</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Rutten</surname><given-names>FH</given-names></name>, <name name-style="western"><surname>van der Meer</surname><given-names>P</given-names></name></person-group>; <collab>Authors/Task Force M, Document R</collab>. 
<article-title>2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC</article-title>. <source>Eur J Heart Fail</source><year>2016</year>;<volume>18</volume>:<fpage>891</fpage>&#x02013;<lpage>975</lpage>.<pub-id pub-id-type="pmid">27207191</pub-id></mixed-citation></ref><ref id="ehx355-B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Regitz-Zagrosek</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Blomstrom Lundqvist</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Borghi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cifkova</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ferreira</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Foidart</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Gibbs</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Gohlke-Baerwolf</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gorenek</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Iung</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kirby</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Maas</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Morais</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nihoyannopoulos</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Pieper</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Presbitero</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Roos-Hesselink</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Schaufelberger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Seeland</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Torracca</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bax</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Auricchio</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Baumgartner</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ceconi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Dean</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Deaton</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fagard</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Funck-Brentano</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hasdai</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hoes</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Knuuti</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kolh</surname><given-names>P</given-names></name>, <name name-style="western"><surname>McDonagh</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Moulin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Poldermans</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Popescu</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Reiner</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Sechtem</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Sirnes</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Torbicki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vahanian</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Windecker</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Aguiar</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Al-Attar</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Garcia</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Antoniou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Coman</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Elkayam</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Gomez-Sanchez</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Gotcheva</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kiss</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Kitsiou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Konings</surname><given-names>KT</given-names></name>, <name name-style="western"><surname>Lip</surname><given-names>GY</given-names></name>, <name name-style="western"><surname>Manolis</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mebaaza</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mintale</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Morice</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Mulder</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Pasquet</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Priori</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Salvador</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Shotan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Silversides</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Skouby</surname><given-names>SO</given-names></name>, <name name-style="western"><surname>Stein</surname><given-names>JI</given-names></name>, <name name-style="western"><surname>Tornos</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Vejlstrup</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Warnes</surname><given-names>C.</given-names></name></person-group>
<article-title>ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)</article-title>. <source>Eur Heart J</source><year>2011</year>;<volume>32</volume>:<fpage>3147</fpage>&#x02013;<lpage>3197</lpage>.<pub-id pub-id-type="pmid">21873418</pub-id></mixed-citation></ref><ref id="ehx355-B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Halkein</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tabruyn</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Ricke-Hoch</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Haghikia</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>NQ</given-names></name>, <name name-style="western"><surname>Scherr</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Castermans</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Malvaux</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lambert</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Thiry</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sliwa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Noel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Martial</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Struman</surname><given-names>I.</given-names></name></person-group>
<article-title>MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy</article-title>. <source>J Clin Invest</source><year>2013</year>;<volume>123</volume>:<fpage>2143</fpage>&#x02013;<lpage>2154</lpage>.<pub-id pub-id-type="pmid">23619365</pub-id></mixed-citation></ref><ref id="ehx355-B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kaminski</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Podewski</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bonda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Schaefer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sliwa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Forster</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Quint</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Landmesser</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Doerries</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Luchtefeld</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Poli</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Balligand</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Desjardins</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ansari</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Struman</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>NQ</given-names></name>, <name name-style="western"><surname>Zschemisch</surname><given-names>NH</given-names></name>, <name name-style="western"><surname>Klein</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Heusch</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schulz</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hilfiker</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Drexler</surname><given-names>H.</given-names></name></person-group>
<article-title>A cathepsin D-cleaved 16&#x02009;kDa form of prolactin mediates postpartum cardiomyopathy</article-title>. <source>Cell</source><year>2007</year>;<volume>128</volume>:<fpage>589</fpage>&#x02013;<lpage>600</lpage>.<pub-id pub-id-type="pmid">17289576</pub-id></mixed-citation></ref><ref id="ehx355-B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Patten</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Rana</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Shahul</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rowe</surname><given-names>GC</given-names></name>, <name name-style="western"><surname>Jang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hacker</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Rhee</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Mitchell</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mahmood</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Hess</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Farrell</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Koulisis</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Khankin</surname><given-names>EV</given-names></name>, <name name-style="western"><surname>Burke</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Tudorache</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Bauersachs</surname><given-names>J</given-names></name>, <name name-style="western"><surname>del Monte</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Karumanchi</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Arany</surname><given-names>Z.</given-names></name></person-group>
<article-title>Cardiac angiogenic imbalance leads to peripartum cardiomyopathy</article-title>. <source>Nature</source><year>2012</year>;<volume>485</volume>:<fpage>333</fpage>&#x02013;<lpage>338</lpage>.<pub-id pub-id-type="pmid">22596155</pub-id></mixed-citation></ref><ref id="ehx355-B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ricke-Hoch</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bultmann</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Stapel</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Condorelli</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Rinas</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Sliwa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Scherr</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D.</given-names></name></person-group>
<article-title>Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress</article-title>. <source>Cardiovasc Res</source><year>2014</year>;<volume>101</volume>:<fpage>587</fpage>&#x02013;<lpage>596</lpage>.<pub-id pub-id-type="pmid">24448315</pub-id></mixed-citation></ref><ref id="ehx355-B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mejia-Rodriguez</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Herrera-Abarca</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Ceballos-Reyes</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Avila-Diaz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Prado-Uribe</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Belio-Caro</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Salinas-Gonzalez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vega-Gomez</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Alvarez-Aguilar</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lindholm</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Garcia-Lopez</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Paniagua</surname><given-names>R.</given-names></name></person-group>
<article-title>Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease</article-title>. <source>Biomed Res Int</source><year>2013</year>;<volume>2013</volume>:<fpage>104059.</fpage><pub-id pub-id-type="pmid">23984312</pub-id></mixed-citation></ref><ref id="ehx355-B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Haghikia</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Podewski</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Libhaber</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Labidi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fischer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Roentgen</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tsikas</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jordan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lichtinghagen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>von Kaisenberg</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Struman</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Bovy</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sliwa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bauersachs</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D.</given-names></name></person-group>
<article-title>Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy</article-title>. <source>Basic Res Cardiol</source><year>2013</year>;<volume>108</volume>:<fpage>366.</fpage><pub-id pub-id-type="pmid">23812247</pub-id></mixed-citation></ref><ref id="ehx355-B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sliwa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Blauwet</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Tibazarwa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Libhaber</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Smedema</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>A</given-names></name>, <name name-style="western"><surname>McMurray</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yamac</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Labidi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Struman</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D.</given-names></name></person-group>
<article-title>Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study</article-title>. <source>Circulation</source><year>2010</year>;<volume>121</volume>:<fpage>1465</fpage>&#x02013;<lpage>1473</lpage>.<pub-id pub-id-type="pmid">20308616</pub-id></mixed-citation></ref><ref id="ehx355-B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Haghikia</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Podewski</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Berliner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sonnenschein</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fischer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Angermann</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Bohm</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rontgen</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bauersachs</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D.</given-names></name></person-group>
<article-title>Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy</article-title>. <source>Clin Res Cardiol</source><year>2015</year>;<volume>104</volume>:<fpage>911</fpage>&#x02013;<lpage>917</lpage>.<pub-id pub-id-type="pmid">26026286</pub-id></mixed-citation></ref><ref id="ehx355-B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>McNamara</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Elkayam</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Alharethi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Damp</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hsich</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ewald</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Modi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Alexis</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Ramani</surname><given-names>GV</given-names></name>, <name name-style="western"><surname>Semigran</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Haythe</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Markham</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Marek</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gorcsan</surname><given-names>J</given-names><suffix>3rd</suffix></name>, <name name-style="western"><surname>Wu</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Halder</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Pisarcik</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>LT</given-names></name>, <name name-style="western"><surname>Fett</surname><given-names>JD</given-names></name></person-group>; <collab>Investigators I</collab>. 
<article-title>Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy)</article-title>. <source>J Am Coll Cardiol</source><year>2015</year>;<volume>66</volume>:<fpage>905</fpage>&#x02013;<lpage>914</lpage>.<pub-id pub-id-type="pmid">26293760</pub-id></mixed-citation></ref><ref id="ehx355-B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Biteker</surname><given-names>M.</given-names></name></person-group>
<article-title>Peripartum cardiomyopathy in Turkey</article-title>. <source>Int J Cardiol</source><year>2012</year>;<volume>158</volume>:<fpage>e60</fpage>&#x02013;<lpage>e61</lpage>.<pub-id pub-id-type="pmid">22100181</pub-id></mixed-citation></ref><ref id="ehx355-B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Blauwet</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Libhaber</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Forster</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Tibazarwa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mebazaa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sliwa</surname><given-names>K.</given-names></name></person-group>
<article-title>Predictors of outcome in 176 South African patients with peripartum cardiomyopathy</article-title>. <source>Heart</source><year>2013</year>;<volume>99</volume>:<fpage>308</fpage>&#x02013;<lpage>313</lpage>.<pub-id pub-id-type="pmid">23118348</pub-id></mixed-citation></ref><ref id="ehx355-B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fett</surname><given-names>JD.</given-names></name></person-group>
<article-title>Peripartum cardiomyopathy. Insights from Haiti regarding a disease of unknown etiology</article-title>. <source>Minn Med</source><year>2002</year>;<volume>85</volume>:<fpage>46</fpage>&#x02013;<lpage>48</lpage>.</mixed-citation></ref><ref id="ehx355-B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fett</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Christie</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Carraway</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>JG.</given-names></name></person-group>
<article-title>Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution</article-title>. <source>Mayo Clin Proc</source><year>2005</year>;<volume>80</volume>:<fpage>1602</fpage>&#x02013;<lpage>1606</lpage>.<pub-id pub-id-type="pmid">16342653</pub-id></mixed-citation></ref><ref id="ehx355-B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kamiya</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Kitakaze</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ishibashi-Ueda</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Nakatani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Murohara</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tomoike</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ikeda</surname><given-names>T.</given-names></name></person-group>
<article-title>Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese Nationwide survey of peripartum cardiomyopathy</article-title>. <source>Circ J</source><year>2011</year>;<volume>75</volume>:<fpage>1975</fpage>&#x02013;<lpage>1981</lpage>.<pub-id pub-id-type="pmid">21617320</pub-id></mixed-citation></ref><ref id="ehx355-B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pillarisetti</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kondur</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Alani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vacek</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Weiner</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Ellerbeck</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Schreiber</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lakkireddy</surname><given-names>D.</given-names></name></person-group>
<article-title>Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use</article-title>
<source>. J Am Coll Cardiol</source>
<year>2014</year>;<volume>63</volume>(25&#x02009;Pt A):<fpage>2831</fpage>&#x02013;<lpage>2839</lpage>.<pub-id pub-id-type="pmid">24814494</pub-id></mixed-citation></ref><ref id="ehx355-B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sliwa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Forster</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Tibazarwa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Libhaber</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yip</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D.</given-names></name></person-group>
<article-title>Long-term outcome of peripartum cardiomyopathy in a population with high seropositivity for human immunodeficiency virus</article-title>. <source>Int J Cardiol</source><year>2011</year>;<volume>147</volume>:<fpage>202</fpage>&#x02013;<lpage>208</lpage>.<pub-id pub-id-type="pmid">19751951</pub-id></mixed-citation></ref><ref id="ehx355-B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Haghikia</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tongers</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Berliner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Konig</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Schafer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brehm</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bohm</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bauersachs</surname><given-names>J.</given-names></name></person-group>
<article-title>Early ivabradine treatment in patients with acute peripartum cardiomyopathy: subanalysis of the German PPCM registry</article-title>. <source>Int J Cardiol</source><year>2016</year>;<volume>216</volume>:<fpage>165</fpage>&#x02013;<lpage>167</lpage>.<pub-id pub-id-type="pmid">27156059</pub-id></mixed-citation></ref><ref id="ehx355-B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hopp</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Haider</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Iffy</surname><given-names>L.</given-names></name></person-group>
<article-title>Myocardial infarction postpartum in patients taking bromocriptine for the prevention of breast engorgement</article-title>. <source>Int J Cardiol</source><year>1996</year>;<volume>57</volume>:<fpage>227</fpage>&#x02013;<lpage>232</lpage>.<pub-id pub-id-type="pmid">9024910</pub-id></mixed-citation></ref><ref id="ehx355-B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Iffy</surname><given-names>L</given-names></name>, <name name-style="western"><surname>O'donnell</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Correia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hopp</surname><given-names>L.</given-names></name></person-group>
<article-title>Severe cardiac dysrhythmia in patients using bromocriptine postpartum</article-title>. <source>Am J Ther</source><year>1998</year>;<volume>5</volume>:<fpage>111</fpage>&#x02013;<lpage>115</lpage>.<pub-id pub-id-type="pmid">10099047</pub-id></mixed-citation></ref><ref id="ehx355-B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Haghikia</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rontgen</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Vogel-Claussen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Schwab</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Westenfeld</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ehlermann</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Berliner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Podewski</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bauersachs</surname><given-names>J.</given-names></name></person-group>
<article-title>Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study</article-title>. <source>ESC Heart Fail</source><year>2015</year>;<volume>2</volume>:<fpage>139</fpage>&#x02013;<lpage>149</lpage>.<pub-id pub-id-type="pmid">27774259</pub-id></mixed-citation></ref><ref id="ehx355-B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Haghikia</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kaya</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Schwab</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Westenfeld</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ehlermann</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bachelier</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Oettl</surname><given-names>R</given-names></name>, <name name-style="western"><surname>von Kaisenberg</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Katus</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Bauersachs</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D.</given-names></name></person-group>
<article-title>Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy</article-title>. <source>Basic Res Cardiol</source><year>2015</year>;<volume>110</volume>:<fpage>60.</fpage><pub-id pub-id-type="pmid">26519371</pub-id></mixed-citation></ref><ref id="ehx355-B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ware</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mazaika</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Yasso</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>DeSouza</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Cappola</surname><given-names>TP</given-names></name>, <name name-style="western"><surname>Tsai</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kamiya</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Mazzarotto</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Cook</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Halder</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Pisarcik</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hanley-Yanez</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Alharethi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Damp</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hsich</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Elkayam</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Sheppard</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kealey</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Alexis</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ramani</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Safirstein</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Boehmer</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pauly</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Wittstein</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Thohan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Zucker</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gorcsan</surname><given-names>J</given-names><suffix>3rd</suffix></name>, <name name-style="western"><surname>McNamara</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Seidman</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Seidman</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Arany</surname><given-names>Z</given-names></name></person-group>; <collab>Imac, Investigators I</collab>. 
<article-title>Shared genetic predisposition in peripartum and dilated cardiomyopathies</article-title>. <source>N Engl J Med</source><year>2016</year>;<volume>374</volume>:<fpage>233</fpage>&#x02013;<lpage>241</lpage>.<pub-id pub-id-type="pmid">26735901</pub-id></mixed-citation></ref></ref-list></back></article>